The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention
Abstract
Although the balance of recent evidence supports the efficacy of antiretroviral (ARV)-based pre-exposure prophylaxis (PrEP) against HIV-1 infection, recent negative trial results are perplexing. Of seven trials with available HIV endpoints, three different products have been tested: tenofovir 1% vaginal gel, oral tenofovir disoproxil fumarate (TDF) tablets, and TDF/emtricitabine tablets. Six of these trials were conducted exclusively in sub-Saharan Africa; all found the products to be well tolerated, and four demonstrated effectiveness. Furthermore, the HIV Prevention Trial Network (HPTN) 052 trial recently confirmed that antiretroviral treatment leads to 96% reduction in transmission to HIV-negative partners in HIV-serodiscordant couples. These results, along with human and animal data, provide substantial evidence for the efficacy of antiretroviral-based HIV prevention. Yet assessment of oral TDF/emtricitabine in the FEM-PrEP study and of oral and vaginal tenofovir in the Microbicide Trial Network (MTN)-003 trial (VOICE) was stopped for futility. How do we make sense of these discrepant results? We believe that adherence is a key factor, although it cannot be the only factor. Expanding upon a recent editorial in the Lancet, we discuss the impact of suboptimal product adherence on PrEP efficacy in the context of variable drug concentration at the exposure site, integrity of the vaginal epithelium, and the role of acute infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of HIV-1 infection with early antiretroviral therapy.
Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G., Kumwenda, J., Grinsztejn, B., Pilotto, J. H. S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105243 · Cited by 6,873
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096 · cited 2×
“Moreover, adherence by pill count was 84% in TDF2 [11] and 89–95% in iPrEx [7], although drug levels were detectable in only 54% of a random subsample of men [8].”
BackgroundAbdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., Kharsany, A. B. M., Sibeko, S., Mlisana, K. P., Omar, Z., et al. (2010) · Science · doi:10.1126/science.1193748 · Cited by 2,435 · cited 10×
“Applicators were used pericoitally in 72% of reported sex acts in CAPRISA004 (90% by selfreport), with more protection (54”
BackgroundMethodInfluentialFreeman, E. E., Weiss, H. A., Glynn, J. R., Cross, P. L., Whitworth, J. A., & Hayes, R. J. (2006) · AIDS · doi:10.1097/01.aids.0000198081.09337.a7 · Cited by 1,192
Simoni, J. M., Kurth, A. E., Pearson, C. R., Pantalone, D. W., Merrill, J. O., & Frick, P. A. (2006) · AIDS and Behavior · doi:10.1007/s10461-006-9078-6 · Cited by 653
Jackson, J. B., Musoke, P., Fleming, T., Guay, L. A., Bagenda, D., Allen, M., Nakabiito, C., Sherman, J., Bakaki, P., Owor, M., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14341-3 · Cited by 524
Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study
Heffron, R., Donnell, D., Rees, H., Celum, C., Mugo, N., Were, E., de Bruyn, G., Nakku-Joloba, E., Ngure, K., Kiarie, J., et al. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70247-x · Cited by 425
Patterson, K. B., Prince, H. A., Kraft, E., Jenkins, A. J., Shaheen, N. J., Rooney, J. F., Cohen, M. S., & Kashuba, A. D. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003174 · Cited by 355
García-Lerma, J. G., Otten, R. A., Qari, S. H., Jackson, E., Cong, M.-E., Masciotra, S., Luo, W., Kim, C., Adams, D. R., Monsour, M., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050028 · Cited by 350
Peterson, L., Taylor, D., Roddy, R., Belai, G., Phillips, P., Nanda, K., Grant, R., Clarke, E. E. K., Doh, A. S., Ridzon, R., et al. (2007) · PLoS Clinical Trials · doi:10.1371/journal.pctr.0020027 · Cited by 277
Low, N., Chersich, M. F., Schmidlin, K., Egger, M., Francis, S. C., H. H. M. van de Wijgert, J., Hayes, R. J., Baeten, J. M., Brown, J., Delany-Moretlwe, S., et al. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000416 · Cited by 271
Self-citationKarim, S. S. A., Kashuba, A. D., Werner, L., & Karim, Q. A. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60878-7 · Cited by 221
The natural history of medication compliance in a drug trial: Limitations of pill counts
Rudd, P., Byyny, R. L., Zachary, V., LoVerde, M. E., Titus, C., Mitchell, W. D., & Marshall, G. (1989) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1989.122 · Cited by 205
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection
Anderson, P. L., Kiser, J. J., Gardner, E. M., Rower, J. E., Meditz, A., & Grant, R. M. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq447 · Cited by 192
In Vitro and Ex Vivo Testing of Tenofovir Shows It Is Effective As an HIV-1 Microbicide
Rohan, L. C., Moncla, B. J., Kunjara Na Ayudhya, R. P., Cost, M., Huang, Y., Gai, F., Billitto, N., Lynam, J. D., Pryke, K., Graebing, P., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009310 · Cited by 183
Tien, D., Schnaare, R. L., Kang, F., Cohl, G., McCormick, T. J., Moench, T. R., Doncel, G., Watson, K., Buckheit, R. W., Lewis, M. G., et al. (2005) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2005.21.845 · Cited by 178
Hel, Z., Stringer, E., & Mestecky, J. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0018 · Cited by 166
Intravaginal Practices, Vaginal Infections and HIV Acquisition: Systematic Review and Meta-Analysis
Hilber, A. M., Francis, S. C., Chersich, M., Scott, P., Redmond, S. M. S., Bender, N., Miotti, P., Temmerman, M., & Low, N. N. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009119 · Cited by 145
Kaul, R., Nagelkerke, N. J. D., Kimani, J., NGUGI, E. N., Bwayo, J. J., MacDonald, K. S., Rebbaprgada, A., Fonck, K., Temmerman, M., Ronald, A., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/522006 · Cited by 139
Probability of HIV Transmission During Acute Infection in Rakai, Uganda
Pinkerton, S. D. (2007) · AIDS and Behavior · doi:10.1007/s10461-007-9329-1 · Cited by 131
Concurrent Partnerships, Acute Infection and HIV Epidemic Dynamics Among Young Adults in Zimbabwe
Goodreau, S. M., Cassels, S. L., Kasprzyk, D., Montaño, D. E., Greek, A. A., & Morris, M. (2010) · AIDS and Behavior · doi:10.1007/s10461-010-9858-x · Cited by 124
Topical Tenofovir, a Microbicide Effective against HIV, Inhibits Herpes Simplex Virus-2 Replication
Andreï, G., Lisco, A., Vanpouille, C., Introini, A., Balestra, E., van den Oord, J., Cihlář, T., Perno, C. F., Snoeck, R., Margolis, L. B., et al. (2011) · Cell Host & Microbe · doi:10.1016/j.chom.2011.08.015 · Cited by 120
Antiretroviral prophylaxis: a defining moment in HIV control
Karim, S. S. A., & Karim, Q. A. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61136-7 · Cited by 119
No HIV stage is dominant in driving the HIV epidemic in sub-Saharan Africa
Abu-Raddad, L. J., & Longini, I. M. (2008) · AIDS · doi:10.1097/qad.0b013e3282f8af84 · Cited by 112
Open access for the non-English-speaking world: overcoming the language barrier
Fung, I. C. (2008) · Emerging Themes in Epidemiology · doi:10.1186/1742-7622-5-1 · Cited by 108
Herpes simplex virus type 2: a key role in HIV incidence
Glynn, J. R., Biraro, S., & Weiss, H. A. (2009) · AIDS · doi:10.1097/qad.0b013e32832e15e8 · Cited by 99
Schwartz, J. L., Rountree, W., Kashuba, A. D. M., Brache, V., Creinin, M. D., Poindexter, A. N., & Kearney, B. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025974 · Cited by 97
Montgomery, E., van der Straten, A., Chidanyika, A., Chipato, T., Jaffar, S. S., & PADIAN, N. S. (2010) · AIDS and Behavior · doi:10.1007/s10461-010-9806-9 · Cited by 84
Nuttall, J. P., Kashuba, A. D. M., Wang, R., White, N., Allen, P., Roberts, J. A., & Romano, J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00597-11 · Cited by 72
Persisting with prevention: The importance of adherence for HIV prevention
Weiss, H. A., Wasserheit, J. N., Barnabas, R. V., Hayes, R., & Abu-Raddad, L. J. (2008) · Emerging Themes in Epidemiology · doi:10.1186/1742-7622-5-8 · Cited by 72
Lack of Effect of Tenofovir Disoproxil Fumarate on Pharmacokinetics of Hormonal Contraceptives
Kearney, B. P., & Mathias, A. A. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.8.924 · Cited by 49
Montgomery, E., van der Straten, A., & Torjesen, K. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31821d33d6 · Cited by 37
Determinants of Differential HIV Incidence Among Women in Three Southern African Locations
Napierala, S., Weiss, H. A., Montgomery, E., Blanchard, K., de Bruyn, G., Ramjee, G., Chipato, T., PADIAN, N. S., & van der Straten, A. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182254038 · Cited by 34
Stuart, G. S., Moses, A., Corbett, A., Phiri, G., Kumwenda, W., Mkandawire, N., Chintedze, J., Malunga, G., Hosseinipour, M. C., Cohen, M. S., et al. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31822b8bf8 · Cited by 28
HIV Prevention in Women: Next Steps
Vermund, S. H., & Damme, L. V. (2011) · Science · doi:10.1126/science.331.6015.284-a · Cited by 19
Cited by
Sexually Transmitted Diseases Treatment Guidelines, 2010
(2011) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2011.04.006 · Cited by 2,076
Use of a vaginal ring containing dapivirine for HIV-1 prevention in women.
Baeten, J. M., Palanee-Phillips, T., Brown, E. R., Schwartz, K., Soto-Torres, L. E., Govender, V., Mgodi, N. M., Matovu Kiweewa, F., Nair, G., Mhlanga, F., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506110 · Cited by 772
Self-citationLiu, A. Y., Cohen, S. E., Vittinghoff, E., Anderson, P. L., Doblecki-Lewis, S., Bacon, O., Chege, W., Postle, B. S., Matheson, T., Amico, K. R., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.4683 · Cited by 602
“The incidence (95% CI) of STIs per 100 person-years was 48 (42-55) for C trachomatis, 43 (37-49) for N gonorrhoeae, 12 (9-16) for syphilis, and 90 (81-99) for any STI; in each case, the incidence was stable across quarterly intervals (all, P > .”
BackgroundUse of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women
Baeten, J. M., Palanee-Phillips, T., Brown, E. R., Schwartz, K., Soto-Torres, L. E., Govender, V., Mgodi, N. M., Kiweewa, F. M., Nair, G., Mhlanga, F., et al. (2016) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000489577.60775.40 · Cited by 372
Self-citationDefining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm
Haberer, J. E., Bangsberg, D. R., Baeten, J. M., Curran, K., Koechlin, F., Amico, K. R., Anderson, P., Mugo, N., Venter, F., Goicochea, P., et al. (2015) · AIDS · doi:10.1097/qad.0000000000000647 · Cited by 319
Self-citation
Metadata
- Authors
- van der Straten, A., Van Damme, L., Haberer, J. E., & Bangsberg, D. R.
- Venue
- AIDS
- Published
- 2012-04-24
- Volume
- 26
- Issue
- 7
- Pages
- F13-F19
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2324968015
- Cited by
- 297
- References
- 35
- FWCI
- 35.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.